+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the anti-tumor effects of amivantamab combined with pembrolizumab and carboplatin compared to pembrolizumab, 5-fluorouracil, and platinum therapy in people with recurrent or metastatic head and neck squamous cell carcinoma HNSCC who have not received prior treatment for their advanced cancer. HNSCC affects tissues in the mouth and throat, and this study focuses on treatment-naive participants in this setting. Participants are assigned to one of two groups one receives pembrolizumab, amivantamab, and carboplatin, while the other receives pembrolizumab, 5-fluorouracil given as a 4-day infusion, and either carboplatin or cisplatin. The study compares these treatment combinations to assess their effects on the cancer over a period of up to about 3 years and 7 months. During the study, participants undergo evaluations including imaging scans to measure tumor response using RECIST criteria, blood tests to monitor drug levels and antibodies, and quality of life questionnaires focused on head and neck symptoms and overall health. Researchers track overall survival, tumor response rates, progression-free survival, duration of response, side effects, and symptom changes. The study involves regular visits for treatment and monitoring throughout the treatment and follow-up period.

Age: 18Years +All GendersPhase 3
205 locations
P

Actively Recruiting

Researchers are evaluating the effects of different doses of brivekimig compared to a placebo in adults with moderate to severe Crohns disease. This phase 2, randomized, double-blind study aims to assess the treatments impact on endoscopic response and remission. The trial includes participants who have not adequately responded to standard therapies. The study is sponsored by Sanofi and plans to enroll adults aged 18 to 75 years. Participants will be randomly assigned to receive one of two dosing regimens of brivekimig or a placebo, all administered by subcutaneous injection. The treatment period can last up to 158 weeks and includes an optional open-label long-term extension lasting up to 104 weeks for eligible participants. The study design includes three groups two experimental brivekimig dose regimens and one placebo group. Throughout the study, participants will undergo assessments to measure endoscopic response at week 16 and other clinical outcomes such as remission rates, symptom scores, serum drug levels, and safety monitoring for adverse events. Evaluations include Crohns Disease Activity Index scores, patient-reported outcomes, and endoscopic examinations up to week 52. The total duration of participation may be up to 168 weeks, with ongoing safety and efficacy monitoring.

Age: 18Years - 75YearsAll GendersPhase 2
78 locations
E

Actively Recruiting

Researchers are evaluating the safety and effects of the study medicine PF-07248144 combined with fulvestrant for treating hormone receptor-positive HR-positive, HER2-negative advanced or metastatic breast cancer. This study focuses on patients whose cancer has progressed after prior treatment with cyclin dependent kinase CDK 46 inhibitor-based therapy. HR-positive breast cancer cells grow in response to hormones like estrogen and progesterone, while HER2-negative cells have little or no HER2 protein, which affects cancer growth and spread. Participants are divided into two groups one receives PF-07248144 tablets daily at home in 28-day cycles along with fulvestrant injections given at the clinic. The other group receives everolimus tablets daily combined with the investigators choice of endocrine therapy, either exemestane tablets or fulvestrant injections. The study compares the safety and effects of PF-07248144 plus fulvestrant against these standard treatments. During the study, participants will have regular clinic visits for injections and monitoring. Researchers will assess disease progression and survival, measure tumor response, record any side effects, and perform laboratory tests including ECGs and drug level checks. The main outcome is progression-free survival, tracked for up to two years, while other safety and effectiveness measures will be followed for up to five years. Total participation may extend over several years depending on individual outcomes.

Age: 18Years +All GendersPhase 3
433 locations
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of a topical spray called YJ001 for patients with diabetic peripheral neuropathic pain DPNP. This Phase I, randomized, double-blind, placebo-controlled study includes adults aged 18 to 80 years and is conducted at a single study center. The study involves two dose levels and aims to assess multiple ascending doses applied topically to both feet and below the ankles. Participants are assigned to one of two cohorts receiving either 296 mg or 414 mg doses of YJ001, each cohort including 12 subjects with 10 receiving the active spray and 2 receiving placebo. The treatment is administered as multiple sprays on both feet once in the morning on Days 1 and 2, then twice daily morning and evening from Days 3 to 11. The Safety Review Committee evaluates safety and pharmacokinetics data after each cohort to decide on dose escalation or other study actions. Before starting treatment, subjects undergo screening and a baseline pain rating period from Day -7 to Day -1. They stay in the clinic from Day -1 through Day 17 for treatment and observation, with follow-up by phone 2 days after discharge. Researchers monitor safety through adverse events, laboratory tests, and skin reactions for about one year. Pharmacokinetics and efficacy are assessed through various measurements during and after dosing, ensuring detailed evaluation of the treatments effects and tolerability.

Age: 18Years - 80YearsAll GendersPhase 1
1 location
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of adagrasib MRTX849 alone and combined with pembrolizumab in patients with advanced or metastatic non-small cell lung cancer NSCLC who have a KRAS G12C mutation. The study includes both Phase 2 and Phase 3 portions, focusing on patients eligible for first-line treatment with varying levels of PD-L1 expression. The trial compares adagrasib combined with pembrolizumab to pembrolizumab alone in patients with high PD-L1 expression. In Phase 2, patients are divided into three groups based on PD-L1 TPS scores two groups with scores below 1% receive either adagrasib monotherapy or adagrasib plus pembrolizumab, and one group with scores of 1% or higher receives the combination. Phase 3 randomizes patients with PD-L1 TPS of 50% or higher to receive either adagrasib plus pembrolizumab or pembrolizumab alone. Adagrasib is taken orally twice daily, while pembrolizumab is given intravenously every three weeks. Participants undergo regular assessments including brain imaging, tumor measurements, and quality of life questionnaires. Researchers monitor treatment effects, safety, drug levels in blood, and lung cancer symptoms over periods of up to 22 months in Phase 2 and 36 months in Phase 3. The study also evaluates progression-free survival, response duration, and other outcomes to understand the treatments impact.

Age: 18Years +All GendersPhase 2Phase 3
770 locations
R

Actively Recruiting

Researchers are evaluating overall survival in patients with advanced metastatic or locally recurrent breast cancer who have no approved alternative therapies available. This Phase 3, multicenter, randomized, open-label study compares the Bria-IMT regimen combined with the checkpoint inhibitor Retifanlimab against treatment chosen by patients or physicians, known as Treatment of Physicians Choice TPC. The study also investigates the activity of the Bria-IMT regimen alone compared to its combination with Retifanlimab. Participants are initially randomized into three groups Bria-IMT regimen plus Retifanlimab combination therapy, TPC, and Bria-IMT regimen alone monotherapy. After enrolling the first 150 patients, the monotherapy group will be discontinued, and those patients may switch to combination therapy. The Bria-IMT regimen includes cyclophosphamide administered 2-3 days before SV-BR-1-GM given intradermally in four inoculations, followed by checkpoint inhibitor infusion plus interferon injections at inoculation sites over three days. Treatment cycles repeat every three weeks, while TPC is given per standard care at each site. Imaging assessments are conducted every six weeks twice, then every eight weeks thereafter unless disease progression or safety issues occur. During the study, participants will have regular therapy cycles and imaging assessments to monitor disease progression. Researchers will evaluate outcomes such as overall survival up to 60 months, progression-free survival, clinical benefit rate, overall response rate, quality of life, and central nervous system event-free survival. Safety and treatment effects will be closely monitored throughout the trial, which is expected to complete by June 2028.

Age: 18Years +All GendersPhase 3
79 locations
G

Actively Recruiting

Researchers are studying a new medicine called PF-08634404 to see how well it works when combined with chemotherapy in adults who have extensive-stage small cell lung cancer ES-SCLC, a fast-growing type of lung cancer that has spread widely. This study includes two parts the first part focuses on checking the safety and tolerance of the medicine with chemotherapy, while the second part compares this combination to an approved treatment using atezolizumab and chemotherapy. Participants will receive treatments through intravenous infusions in repeated cycles. Some participants may continue receiving PF-08634404 alone after the initial combined treatment phase. The study involves random assignment to either the PF-08634404 plus chemotherapy group or the atezolizumab plus chemotherapy group. During the study, participants will have regular assessments including scans to measure tumor response, physical exams, laboratory tests, and questionnaires to evaluate quality of life. The researchers will track outcomes such as tumor shrinkage, overall survival, adverse events, and treatment tolerance up to about two years after treatment completion. Safety and drug concentration in the blood will also be monitored closely throughout the trial.

Age: 18Years +All GendersPhase 2Phase 3
82 locations